Not Yet RecruitingNot Applicable

AET Pilot Intervention

United States, Rwanda224 participantsStarted 2026-09-20

Plain-language summary

This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female patients * Age 18 or older * Pathologic confirmation of ER-positive breast cancer * Clinical or radiographic confirmation of disease localized to the breast and regional lymph nodes * Within 6-36 months of starting AET * Have a cellphone capable of receiving text messages. * Are currently receiving AET at Butaro or satellite clinics. Exclusion Criteria: * Unwilling/Unable to participate * Unable to comprehend study languages (English or Kinyarwanda) * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Pregnant women

What they're measuring

3-month Adherence Rate

Timeframe: 3 months

Trial details

NCT IDNCT07562399

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Temidayo Fadelu, MD

617-632-3779 temidayo_fadelu@dfci.harvard.edu

View on ClinicalTrials.gov More Medication Adherence trials